The Myxedema coma in children and adolescents: A rare endocrine emergency - Personal experience and review of literature Myxedema coma in children and adolescents

Main Article Content

Vincenzo De Sanctis

Keywords

: Myxedema coma, hypothyroidism, iron overload, aplastic anemia, Hashimoto thyroiditis, treatment, prognosis

Abstract

Abstract. Decompensated hypothyroidism, formerly known as myxedema coma, represents the most extreme clinical expression of severe primary or secondary hypothyroidism in which patients exhibit multiple organ abnormalities and progressive mental deterioration. The exact incidence of myxedema coma in adults is not known, but some authors have estimated that is approximately 0.22 per 100.0000 per year in the western world. Myxedema coma is more common in females and during winter months. The diagnosis of myxedema coma is primarily clinical with supportive evidence of the abnormal thyroid function tests. Clinical features vary depending on a several factors including the age of onset and the severity of the disease. In the majority of patients (95%), the cause of underlying hypothyroidism is autoimmunity, i.e., Hashimoto thyroiditis or congenital abnormalities. Rarely it occurs in secondary (central) hypothyroidism, due to thyrotropin deficiency related to pituitary disease, or pituitary-thyroid damage due to iron overload. Treatment consists of thyroid hormone replacement, correction of electrolyte disturbances, passive rewarming, treatment of infections, respiratory and hemodynamic support, and administration of stress-dose glucocorticoids. Prognosis seems to be better in children and adolescents compared to adults. The present review reports personal experience and the literature data on 13 patients.

Downloads

Download data is not yet available.
Abstract 17 |

References

1. Bridwell RE, Willis GC, Gottlieb M, Koyfman A, Long B. Decompensated hypothyroidism: A review for the emergency clinician. Am J Emerg Med. 2021;39:207-12.
2. Thompson MD, Henry RK. Myxedema Coma Secondary to Central Hypothyroidism: A Rare but Real Cause of Altered Mental Status in Pediatrics. Horm Res Paediatr. 2017;87:350-3.
3. Ortiga-Carvalho TM, Chiamolera MI, Pazos-Moura CC, Wondisford FE. Hypothalamus-Pituitary-Thyroid Axis. Compr Physiol. 2016;6:1387-1428.
4. Mebis L, van den Berghe G. The hypothalamus-pituitary-thyroid axis in critical illness. Neth J Med. 2009; 67:332-40.
5. Brent GA. Mechanisms of thyroid hormone action. J Clin Invest. 2012;122:3035-43.
6. Song Y, Yao X, Ying H. Thyroid hormone action in metabolic regulation. Protein Cell. 2011;2:358-68.
7. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001; 344:501-9.
8. Crunkhorn S, Patti ME. Links between thyroid hormone action, oxidative metabolism, and diabetes risk? Thyroid. 2008;18: 227-37.
9. Chatzitomaris A, Scheeler M, Gotzmann M, et al. Second degree AV block and severely impaired contractility in cardiac myxedema: a case report. Thyroid Res. 2015;8:6. doi: 10.1186/s13044-015-0018-2.
10. Majid-Moosa A, Schussler JM, Mora A. Myxedema coma with cardiac tamponade and severe cardiomyopathy. Proc (Bayl Univ Med Cent). 2015;28:509-11.
11. Kerber RE, Sherman B. Echocardiographic evaluation of pericardial effusion in myxedema: incidence
and biochemical and clinical correlations. Circulation.1975;52:823-7.
12. Spitzweg C, Reincke M, Gärtner R. Thyroid emergencies : Thyroid storm and myxedema coma. Internist (Berl). 201758:1011-9. [German].
13.Rodríguez I, Fluiters E, Pérez-Méndez LF, Luna R, Páramo C, García-Mayor RV. Factors associated with mortality of patients with myxoedema coma: prospective study in 11 cases treated in a single institution. J Endocrinol. 2004:180:347-50
14.Wall CR. Myxedema coma: diagnosis and treatment. Am Fam Physician. 2000;62:2485-90.
15. Roberts CG, Ladenson PW. Hypothyroidism. Lancet. 2004;363:793-803.
16. Kwaku MP, Burman KD. Myxedema coma. J Intensive Care Med. 2007;22:224-31.
17. Soliman A, Alhumaidi N, Alali M, Sabt A. An adolescent girl with hypothyroid coma due to autoimmune thyroiditis. ESPE. Endocrine Abs. 2013: 32: P813.
18. De Sanctis V ,Soliman AT, Elsedfy H, Soliman NA, Elalaily R, Elhakim IZ. Myxoedema coma: A report in an adolescent with aplastic anemia and iron overload. Riv Ital Med Adolesc.2016;14:25-8.
19. Chiong YV, Bammerlin E, Mariash CN. Development of an objective tool for the diagnosis of myxedema coma. Transl Res. 2015;166:233-43.
20. Schutt-Aine JC. Hypothyroid myxedema and hyponatremia in an eight-year-old child: A case report. J. Natl. Med. Assoc. 1980; 72: 705–8.
21. Zhu Y, Qiu W, Deng M, Zhu X. Myxedema coma: A case report of pediatric emergency care. Medicine (Baltimore). 2017;96: e6952.
22. Thompson MD, Henry RK. Myxedema Coma Secondary to Central Hypothyroidism: A Rare but Real Cause of Altered Mental Status in Pediatrics. Horm Res Paediatr. 2017;87:350-3.
23. Root JM, Vargas M, Garibaldi LR, Saladino RA. Pediatric Patient With Altered Mental Status and Hypoxemia: Case Report. Pediatr Emerg Care. 201733:486-8.
24. Heksch RA, Henry RK. Myxedema Coma due to Hashimoto Thyroiditis: A Rare but Real Presentation of Failure to Thrive in Infancy. Horm Res Paediatr. 2018;90:332–6.
25. Janson A, Hällström C, Iversen M, Finder M, Elimam A, Nergårdh R. Initial low-dose oral levothyroxine in a child with Down syndrome, myxedema, and cardiogenic shock. Clin Case Rep. 2019;7:1291-6.
26. Wankanit S, Mahachoklertwattana P, Anantasit N, Katanyuwong P, Poomthavorn P. Myxoedema coma in a 2-year-old girl with untreated congenital hypothyroidism: Case report and literature review. J Paediatr Child Health. 2019;55:707-10.
27. Divecha CA, Tullu MS, Deshmukh CT, Karande S. Myxedema Coma in a Pediatric Patient with Down Syndrome. J Pediatr Intensive Care. 2020;9:70-3.
28. Hallett TC, Solomon B, Ciener DA. Congenital hypothyroidism presenting as myxedema coma in a teenager. Am J Emerg Med. 2021;45:688.e1-688.e2.
29. Sterns RH, Nigwekar SU, Hix JK. The treatment of hyponatremia. Semin Nephrol. 2009;29:282–99.
30. Kargili A, Turgut FH, Karakurt F, Kasapoglu B, Kanbay M, Akcay A. A forgotten but important risk factor for severe hyponatremia: myxedema coma. Clinics (Sao Paulo). 2010;65:447-8.
31. Jonklaas J, Bianco AC, Bauer AJ, et al, American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on thyroid hormone replacement. Thyroid. 2014 ;24:1670-751.
32. Pereira VG, Haron ES, Lima-Neto N, Medeiros-Neto G. Management of myxedema coma: report on three successfully treated patients with nasogastric or intravenous administration of triiodothyronine. J Endocrinol Invest. 1982;5:331–4.
33. Sarlis NJ, Gourgiotis L. Thyroid emergencies. Rev Endocr Metab Disord. 2003;4:129-36.
34. Michiels JJ, Schroyens W, Berneman Z, van der Planken M. Acquired von Willebrand syndrome type 1 in hypothyroidism: reversal after treatment with thyroxine. Clin Appl Thromb Hemost. 2001;7:113-5.
35. Ono Y, Ono S, Yasunaga H, Matsui H, Fushimi K, Tanaka Y. Clinical characteristics and outcomes of myxedema coma: analysis of a national inpatient database in Japan. J Epidemiol 2017; 27: 117-22.
36. Mathew V, Misgar RA, Ghosh S, et al. Myxedema coma: a new look into an old crisis. J Thyroid Res. 2011; 2011:493462. doi: 10.4061/2011/493462.
37. Rodriguez I, Fluiters E, Perez-Mendez LF, et al. Factors associated with mortality of patients with myxoedema coma: prospective study in 11 cases treated in a single institution. J Endocrinol. 2004;180:347-50.
38. Pinto-Valdivia M, Vásquez-Kunze S, Pinto-Valdivia JL, Villena-Chávez J. Coma mixedematoso y midazolam : Reporte de caso. Rev Méd Hered. 2012;19;171-4 [Spanish].

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >>